ViiT Health

Non-invasive device to detect blood sugar levels.


Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9

ViiT Health: Fast Facts

ViiT Health is a health tech company that develops computer vision software and hardware with the objective of identifying major health conditions by tracking analytes within the human body.

We currently specialize in glucose measurement through a non-invasive portable device, the Gluco 1.0, which uses Near Infrared Radiation technology and proprietary computer vision software to monitor glucose levels in live tissue.

The Problem

Despite paying more than $10 billion a year to monitor their blood sugar, 60% of the 422 million diabetics around the world are likely to quit treatment because of the cost of supplies and the pain caused by their devices. 

ViiT Health

The Gluco 1.0 is a cost-effective, needle-free glucose measurement device.

Market Size

The Gluco 1.0 will enter the $10 billion global puncture glucometer market servicing more than 422 million diabetics worldwide.

The first country to be activated will be Mexico, where diabetes is the second largest cause of death, with registered numbers of more than 20 million diabetics..

How It Works

With the Gluco 1.0 diabetics can check their blood sugar levels without needles or strips.  

Accurate glucose readings, no finger pricks required.

Traction & Accomplishments 

The Gluco 1.0 has been developed and is currently in Validation Protocols with the National institute for Nutrition in Mexico. To date, it has achieved a better error margin than puncture glucometers, above 90% accuracy. 

We have already formed several alliances in Mexico, the U.S. and Europe, including Softeq for engineering and business development, Mexico’s City Science and Technology Department for validation protocols, the Arrowhead Center from the University of New Mexico, Monaco Foundry for business development in Europe, the Mayan Fund, and Arroba Ingenieria for product iteration.

Meet The Team 

Luis G. Sánchez, founder and president of the board, has been a corporate lawyer and a computer vision entrepreneur. He has a JD in international law from Harvard University and was in the advanced management program at Harvard Business School. He also has experience in top corporate management at Citibank Mexico, Shearman & Sterling, AT&T, Alestra, Chrysler, Daimler, and Walmart.

Luis Fernando de la Maza, is a ​serial entrepreneur and social activist from Mexico City. He created a venture builder at 20 years old, which now holds seven companies. He won the Santander Global Entrepreneurship Program in 2020.

Dr. Josué Álvarez Borrego, head of research and development, is a leading researcher at the Center for Scientific Research and Higher Education, specializing in pattern recognition and image processing. He has published more than 90 academic papers and is the former chairman for the National Optics Academy.

Antonio García, technology consultant, is the associate dean of academic affairs at New Mexico State University’s College of Engineering. He was a foundation professor of bioengineering at ASU. His expertise includes surface and colloid chemistry for diagnostics, drug delivery, biomolecule identification, and medical devices.

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.

Request Access


No updates yet.


No backers yet.

Quick Signup TBD

You must have an account to do this!

the platform

Copyright © 2019 All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.